momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (11703)	9/27/2018 3:37:09 PM
From: scaram(o)uche	Read Replies (1) of 12215

This is the summary that I had seen..... businesswire.com paraphrased.... "Cut the dose in half, and we're pleased that there is no vomiting. There's some nausea, but it's mild. We'd really like to move to 50 mg, as there almost certainly would be vomiting at 200 in broader testing. And who knows what else? But it's just not very effective at that dose, ya know? So we're trying to sell this teeny-tiny narrow window. Feel like buying?" I found this to be weird.... "No patients experienced nausea or vomiting at the 50 mg dose and the overall adverse event profile of this group was similar to the placebo group." Why single out that group, when you're all pumped about managing nausea at 200? Discuss apples, but shine the oranges. Anyway.... it's DEAD. Fodder for a pipeline chart. Given recent observations, it would be wonderful to see them unveil a second generation molecule. Be fun to have access to historical/hysterical charts.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next